By: IPP Bureau
Last updated : July 27, 2026 2:33 pm
The successful inspection marks another regulatory milestone for the company's analytical operations, reinforcing its commitment to quality, regulatory compliance, and data integrity across its global analytical network
Pace Life Sciences, a US-based FDA-registered GMP analytical testing laboratory and CDMO, has successfully completed a US Food and Drug Administration (FDA) inspection of its Small Molecule Center of Excellence in Research Triangle Park, North Carolina.
The successful inspection marks another regulatory milestone for the company's analytical operations, reinforcing its commitment to quality, regulatory compliance, and data integrity across its global analytical network.
Lou Forcellini, Head of Quality Assurance at Pace Life Sciences, said, "Achieving consistent positive FDA inspection outcomes across our analytical network reflects the strength of our quality systems, the expertise of our staff, and our unwavering commitment to scientific excellence.
Each successful inspection strengthens our clients' confidence in our capabilities and reinforces our mission to deliver reliable, high-quality results that ultimately help improve patient lives."
The Research Triangle Park facility provides comprehensive analytical support across the drug development and manufacturing lifecycle.
Its capabilities include storage and stability testing, extractables and leachables (E&L) studies for container closure systems and manufacturing materials, analytical method development and validation, and organic spectroscopy for the characterisation, quantification, and identification of both small and large molecules.